Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > COLUMN
COLUMN
- Boosting Employee Retention in a Competitive Market
April 18, 2024
- How to Paint an Irresistible Picture of Success
March 22, 2024
- Positioning Your Company as an Employer of Choice
February 22, 2024
- Navigating the Evolving Landscape of Medical Affairs: Integrating Insights and Identity for Future Success
February 7, 2024
- How NOT to Write a Job Description
January 26, 2024
- Goal-Setting for 2024: Crushing It
December 20, 2023
- The Power of Referrals and Who to Ask
November 24, 2023
- How Can Innovative Field Force Roles and Ways of Working Create More Impactful Engagement?
November 2, 2023
- 3 Strategies for Attracting Talent Who Aren’t Looking for a Job
October 18, 2023
- How Can You Improve Field Force Productivity in the Age of Digital? Omnichannel Excellence and the Importance of a Strong “Middle Layer”
October 6, 2023
- How to Get 4 Qualified Candidates within 4 Weeks
September 25, 2023
- How Far Has Your Organization Come? Key Lessons Learned from Ongoing Commercial Transformations in Japan
September 11, 2023
- Mission Impossible: Finding the Right Leader to Launch a Disruptive Medical Technology into Japan
August 10, 2023
- How Healthcare Companies Should Hire in the Post-COVID Work Environment
July 19, 2023
- The Impact of a Shrinking Labor Market on the Healthcare Industry
June 23, 2023
- Seven Recruitment Trends in 2023
May 31, 2023
- The Inflation Reduction Act - Implications for Japanese Pharmaceutical Manufacturers
May 19, 2023
- How to Serve and Get Ahead
April 21, 2023
- The Increasing Impact of Real-World Evidence
March 31, 2023
- Rewarding Value and Innovation and Ensuring Financial Viability of the Biopharmaceutical Supply Chain in Japan
March 16, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…